SEC Form 4 · accession 0001209191-18-063255
Myovant Sciences Ltd. · MYOV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kim Sablich
Officer — Chief Commercial Officer
Period of report
Dec 17, 2018
Accepted (ET)
Dec 18, 2018 · 5:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001679082
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Dec 17, 2018 | A | 29,700 | $0.00 | A | 29,700 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $17.28 | Dec 17, 2018 | A | 133,500 | A | — | Dec 16, 2028 | Common Shares | 133,500 | 133,500 | D |
Explanation of responses
- F1Represents common shares underlying a restricted stock unit award.
- F21/4 of the common shares underlying this restricted stock unit award vest on December 17, 2019, and 1/16 of the common shares underlying this restricted stock unit award vest at the end of each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.
- F31/4 of the common shares underlying this option vest on December 17, 2019, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.